Abstract 1752
Background
Lung cancer is one of the most common malignant tumor and the leading cause of cancer mortality worldwide. Metastasis-associated with colon cancer-1 (MACC1) is a key regulator of hepatocyte growth factor/c-Met signaling. It was reported that Sp1 is able to interact with MACC1 to regulate the transcriptional activity of the Met promoter. The aim of this study is to investigate the expression and clinicopathologic significance of MACC1 and Sp1 expression and evaluate their biology in lung adenocarcinoma.
Methods
A total 93 cases of tissue microarray from surgical resection for primary lung adenocarcinoma were used. Clinical and pathologic reports were reviewed for age, sex, tumor size, histological grade, T stage, nodal status, distant metastasis, TNM stage, pleural invasion, lymphovascular invasion and survival outcome. Immunohistochemistry for MACC-1 and Sp1 was performed.
Results
MACC1 overexpression was significantly correlated with lymph nodal status (p = 0.026), pleural invasion (p = 0.030) and survival outcome (p = 0.006). High expression of Sp showed statistical significance with T stage (p = 0.017), TNM stage (p = 0.032), disease progression (p = 0.012) and survival outcome (p = 0.0236). Survival analyses revealed that MACC1 (p = 0.012) and SP1 expression (p = 0.023) were associated with worse overall survival. We found correlations between MACC1 and SP1 expression (p = 0.001). High MACC1 expression was an independent prognostic factor for overall survival (p = 0.041) and SP1 was an independent prognostic factor for progression free survival (p = 0.003).
Conclusions
Our study suggests that high MACC1 and Sp1 expression can be used useful marker to predict worse disease progress and survival outcome of lung adenocarcinoma. Additional study about the mechanism sequence of c-MET expression regulated by Sp1 and MACC1 is required.
Clinical trial identification
Legal entity responsible for the study
individual person
Funding
None
Disclosure
All authors have declared no conflicts of interest.